To include your compound in the COVID-19 Resource Center, submit it here.

NICE rebuffs Abraxane for pancreatic cancer

The U.K.'s NICE issued draft guidance recommending against the use of Abraxane nab-paclitaxel from Celgene Corp. (NASDAQ:CELG) for first-line treatment of metastatic

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE